Cellectar Biosciences (CLRB) Expected to Announce Earnings on Thursday

Cellectar Biosciences (NASDAQ:CLRB) is projected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Cellectar Biosciences to announce earnings of ($0.55) per share and revenue of $12.00 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.88) by $0.55. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cellectar Biosciences Trading Down 1.6%

NASDAQ CLRB opened at $2.52 on Thursday. Cellectar Biosciences has a 1 year low of $2.20 and a 1 year high of $6.52. The company has a fifty day simple moving average of $2.60 and a 200 day simple moving average of $2.91. The company has a market cap of $20.13 million, a P/E ratio of -0.38 and a beta of 0.55.

Wall Street Analysts Forecast Growth

CLRB has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Friday, July 17th. Roth Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Cellectar Biosciences in a research report on Tuesday, May 5th. Wall Street Zen upgraded Cellectar Biosciences to a “hold” rating in a research report on Saturday, June 20th. Brookline Capital Markets raised shares of Cellectar Biosciences to a “strong-buy” rating in a research note on Sunday, July 12th. Finally, LADENBURG THALM/SH SH began coverage on Cellectar Biosciences in a research report on Friday, May 15th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cellectar Biosciences has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Trading of Cellectar Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. DRW Securities LLC increased its holdings in Cellectar Biosciences by 114.2% in the fourth quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 24,089 shares during the last quarter. Geode Capital Management LLC increased its stake in Cellectar Biosciences by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 3,744 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Cellectar Biosciences during the 3rd quarter worth approximately $104,000. Dimensional Fund Advisors LP bought a new position in Cellectar Biosciences in the third quarter valued at approximately $73,000. Finally, Bank of America Corp DE boosted its holdings in shares of Cellectar Biosciences by 25.3% in the fourth quarter. Bank of America Corp DE now owns 206,783 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 41,704 shares during the period. Institutional investors own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc is a clinical?stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope?labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B?cell malignancies, including multiple myeloma and non?Hodgkin lymphoma.